drugset / Trial / NCT06653348

Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke

NCT06653348

Phase 2/3 Recruiting 100 enrolled Mazandaran University of Medical Sciences
RandomizedParallel-groupSingle-blindPrevention

Summary

This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.

Timeline

Start
2024-04-01
Primary completion
2026-07-01
Completion
2026-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ticagrelor Small molecule 60 mg
Subject Ticagrelor Small molecule 90 mg
Background Aspirin Small molecule 80 mg